Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate

[1]  M. Bernardo,et al.  Haloperidol: therapeutic window in schizophrenia. , 1994, Journal of clinical psychopharmacology.

[2]  L. Ereshefsky,et al.  A loading-dose strategy for converting from oral to depot haloperidol. , 1993, Hospital & community psychiatry.

[3]  M. Jann,et al.  Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal , 1993, Schizophrenia Research.

[4]  M. Jann,et al.  Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics , 1993, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[5]  M. Jann,et al.  Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study. , 1991, Journal of clinical psychopharmacology.

[6]  M. Jann,et al.  Pharmacokinetics of Haloperidol , 1989, Clinical pharmacokinetics.

[7]  M. Jann,et al.  Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients , 1989, Biological Psychiatry.

[8]  N. Nair,et al.  The Bioavailability and Pharmacokinetics of Oral and Depot Intramuscular Haloperidol in Schizophrenic Patients , 1987, Journal of clinical pharmacology.

[9]  H. V. van Praag,et al.  Pharmacokinetics and Therapeutic Efficacy of Haloperidol Decanoate after Loading Dose Administration , 1986, British Journal of Psychiatry.

[10]  J. Kane.  Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate. , 1986, Journal of clinical psychopharmacology.

[11]  R. Nayak,et al.  A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. , 1986, Journal of clinical psychopharmacology.

[12]  M. Jann,et al.  Clinical Pharmacokinetics of the Depot Antipsychotics , 1985, Clinical pharmacokinetics.

[13]  J. Da.  Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. , 1984 .

[14]  R. Stanley,et al.  The use of depot neuroleptic haloperidol decanoate , 1984, Acta psychiatrica Scandinavica.

[15]  J. Heykants,et al.  Intramuscular haloperidol decanoate for neuroleptic maintenance therapy Efficacy, dosage schedule and plasma levels AN OPEN MULTICENTER STUDY , 1980, Acta psychiatrica Scandinavica.

[16]  Shih-ku Lin,et al.  Disposition of haloperidol and reduced haloperidol plasma levels after single dose haloperidol decanoate administration , 1995 .

[17]  M. Jann,et al.  Formation of Reduced Haloperidol after Intramuscular Haloperidol Administration in Schizophrenic Patients , 1994 .

[18]  R. Poland,et al.  Haloperidol plasma levels and clinical response: a therapeutic window relationship. , 1992, The American journal of psychiatry.

[19]  L. Ereshefsky,et al.  Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. , 1990, Psychopharmacology bulletin.

[20]  G. Chouinard,et al.  A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. , 1984, Psychopharmacology bulletin.

[21]  Ge Yg,et al.  12-month study of haloperidol decanoate in chronic schizophrenic patients. , 1982 .

[22]  Ge Yg,et al.  Pharmacokinetics of haloperidol decanoate. A 2-year follow-up. , 1982 .

[23]  M. Gibaldi.  Biopharmaceutics and clinical pharmacokinetics , 1977 .